Product Information
DEXTROAMP-AMPHET ER 30 MG CAP is a generic product labeled by Actavis Pharma, Inc., priced at $0.4689 per EA under NDC 00228306111. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Jun 22, 2012. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DEXTROAMP-AMPHET ER 30 MG CAP
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfateStrength
7.5; 7.5; 7.5; 7.5 mg/1; mg/1; mg/1; mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228306111
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA077302FDA Approved
6/22/2012
TE Code
AB1
On Market Since
6/22/2012
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 88.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4689 per EA |
|---|---|
| All-time high | $3.9537 (Jan 15, 2014) |
| All-time low | $0.3360 (May 22, 2024) |
| 52-week high | $0.5895 |
| 52-week low | $0.4621 |
| Median price | $1.5747 |
| Average price | $1.7457 |
| Largest weekly change | +61.4% (Jun 19, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DEXTROAMP-AMPHET ER 30 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMP-AMPHET ER 30 MG CAP, manufactured by Actavis Pharma, Inc., is $0.4689 per EA (NDC 00228306111), effective Aug 19, 2026.
How has the price of DEXTROAMP-AMPHET ER 30 MG CAP changed over time?
Over the history we have for it, the NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has declined 88.0%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DEXTROAMP-AMPHET ER 30 MG CAP?
Since Nov 28, 2013, the NADAC for DEXTROAMP-AMPHET ER 30 MG CAP has ranged from a low of $0.3360 (May 22, 2024) to a high of $3.9537 (Jan 15, 2014), with a median of $1.5747 per EA.
Are there cheaper alternatives to DEXTROAMP-AMPHET ER 30 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMP-AMPHET ER 30 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMP-AMPHET ER 30 MG CAP?
DEXTROAMP-AMPHET ER 30 MG CAP (NDC 00228306111) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.